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Abstract
Cisplatin [cis-dichlorodiammine platinum (II)], a potent chemoimmunotherapeutic drug, activates macrophages to
tumoricidal state which is inhibited by protein tyrosine kinase(s) inhibitor. Cisplatin induces protein tyrosine
phosphorylation of a number of cellular proteins suggesting the involvement of protein tyrosine kinase(s) in the activation
process of macrophages. Therefore, the effect of cisplatin treatment on the expression and activation of lyn, a protein
tyrosine kinase of src family, in macrophages was investigated. The underlying mechanism of lyn expression and activation
was also analyzed. Cisplatin treatment increased lyn expression and activation in macrophages within 5 min of treatment.
The expression and activation of lyn were observed to be biphasic processes in cisplatin-treated macrophages with the first
peak appearing at 15 min and the second peak at 2 h of treatment. The appearance of second phase of lyn activation and
second phase of lyn expression were two unrelated processes. The second peak of lyn activation was produced by the
autocrine action of some soluble product(s) of cisplatin-treated macrophages, whereas the second phase of lyn expression was
due to some intracellular factor. It was further observed that cisplatin-induced lyn expression and activation involves serine/
threonine phosphatases 1/2A, protein tyrosine phosphatases, protein tyrosine kinase and protein kinase C. It was also
observed that Ca2/calmodulin and calmodulin-dependent kinases are involved in the regulation of cisplatin-induced lyn
expression and activation in macrophages. ß 1998 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cisplatin [cis-dichlorodiammine platinum (II)], a
clinically important antitumor drug used for the
treatment of several cancers, especially those of gen-
ito-urinary origin [1,2], has been shown to be a
potent activator of macrophages, human monocytes,
natural killer (NK) cells and lymphokine-activated
killer (LAK) cells [3^18]. The drug has been proved
to be e¡ective alone or in combination with other
drugs or cytokines for the treatment of a variety of
human as well as animal malignancies [2,19].
The mechanism by which cisplatin triggers signal
transduction pathways is a central question in mac-
rophage biology because a classical proof for the
existence of a receptor for cisplatin on macrophages
is lacking [20]. However, notwithstanding an absence
of receptor, cisplatin has been shown to induce tyro-
sine phosphorylation of a number of proteins in
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macrophages [21]. Although the mechanism underly-
ing the stimulated increase in the level of tyrosine
phosphorylation is poorly understood, involvement
of protein tyrosine kinases in this process has been
suggested [21]. It has been observed that genestein, a
speci¢c inhibitor of protein tyrosine kinase [22], in-
hibits cisplatin-induced nuclear factor kappa B (NF-
UB) activation [14], production of tumor necrosis
factor (TNF), interleukin-1 (IL-1), [12], nitric oxide
(NO) [13], oncostatin M (OSM) [16] and expression
of leukocyte function-associated antigen-1 (LFA-1)
[15] by macrophages. Sodium orthovanadate, an in-
hibitor of protein tyrosine phosphatase [23], which
tilts the balance of signalling processes in the favor
of protein tyrosine kinases [24^29], has been ob-
served to augment cisplatin-induced macrophage ac-
tivation [14^16]. These studies provide indirect evi-
dence for the involvement of protein tyrosine
kinase(s) in the cisplatin-induced macrophage activa-
tion process.
Protein tyrosine kinases belong to one of eight
general families which includes the family of src-re-
lated protein tyrosine kinases [30]. The src family of
protein tyrosine kinases is currently composed of
eight members: c-src, c-yes, c-fgr, fyn, lck, hck, lyn,
and blk [30]. The members of src family of protein
tyrosine kinases are membrane-associated protein ty-
rosine kinases which lack transmembrane and exter-
nal amino acid sequences, a feature which distin-
guishes this group from the receptor class of
tyrosine kinases [30]. With regard to hematopoietic
cells, lyn has been found to be preferentially ex-
pressed in macrophages, monocytes, platelets, and
B cells [30]. A number of the receptors of hemato-
poietic cells, including receptors for bacterial lipopo-
lysaccharide (LPS) and interferon-Q (IFN-Q), have
been shown to rely upon the physical association
and activation of lyn protein tyrosine kinase for the
initiation of the cellular signalling processes leading
to a response [30^37]. In addition, Guardy et al. [38]
have shown that activation of lyn tyrosine kinase
activity is a common element in the stimulation of
neutrophils by soluble agonists (fMLP, GM-CSF,
IL-3, -5, -8, NAP-2, and Groa), and particulate ago-
nists (monosodium urate and calcium pyrophosphate
dihydrate crystals, bacteria, and zymosan).
In view of the above observations this study was
undertaken to investigate the e¡ect of cisplatin on
lyn expression and its activation in murine peritoneal
macrophages. To the best of our knowledge, no
study has, so far, investigated the e¡ect of cisplatin
treatment on lyn expression and activation in macro-
phages. Macrophage activation with cisplatin has
been reported to be down-regulated by protein kin-
ase C (PKC) and protein tyrosine kinase (PTK) in-
hibitors and Ca2/calmodulin modulators [12^16,39],
whereas serine/threonine phosphatases 1/2A (PP1/
2A) and protein tyrosine phosphatases (PTPs) inhib-
itors have been found to up-regulate cisplatin-in-
duced macrophage activation [14^16]. Therefore, in
this study we checked the e¡ect of various kinases,
phosphatases inhibitors and Ca2/calmodulin modu-
lators on the expression and activation of lyn in cis-
platin-activated macrophages, in an attempt to cor-
roborate their modulatory e¡ect on cisplatin-induced
macrophage activation.
2. Materials and methods
2.1. Mice
Inbred strain of pathogen free BALB/c mice of
either sex aged 8^10 weeks were used for obtaining
peritoneal macrophages.
2.2. Cell culture and reagents
Medium RPMI 1640, calyculin A, sodium ortho-
vanadate, EGTA, nifedipine, TMB-8, W-7, calmida-
zolium and most of the reagents were purchased
from Sigma Chemicals Co. (St. Louis, Mo, USA).
Fetal calf serum was purchased from Biological In-
dustries (Israel). Okadaic acid was a kind gift from
Dr. Hiroto Fujiki, Vice Director, Saitama Cancer
Research Institute, Ina, Saitama, Japan. Genestein
and H-7 were from LC services Inc., Woburn, MA,
USA. [Q-32P]ATP (speci¢c activity: 3000 mCi/mmol)
was obtained from Bhabha Atomic Research Centre
(Bombay, India). Polyclonal anti-p56lyn (raised
against amino acids 44^63 of human p56lyn) was pur-
chased from Santa Cruz Biotechnology Inc., USA
(Cat# sc-15). All the reagents and culture medium
were free from endotoxin contamination as deter-
mined by the limulus amoebocyte lysate assay (sen-
sitivity limit, 6 0.1 ng/ml).
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2.3. Isolation and activation of peritoneal
macrophages
Macrophage monolayers were prepared as de-
scribed by Sodhi et al. [4], by peritoneal lavage of
BALB/c mice. Macrophages were maintained at
37‡C in a CO2 incubator in RPMI 1640 medium
supplemented with 10% fetal calf serum and antibi-
otics. Before treatment macrophages were serum
starved for 4 h. For activation macrophages
(2U106 cells/well in 24-well tissue culture plate (A/S
Nunc, Denmark)) were incubated with medium alone
or containing optimal dose of cisplatin (10 Wg/ml) for
di¡erent time intervals, or for 15 min in presence or
absence of various inhibitors and modulators as in-
dicated in the results.
2.4. Immunoblotting for lyn
After treatment, macrophage monolayers were
washed in situ with ice-cold PBS containing 1 mM
Na3VO4 and 5 mM EDTA, then lysed in 50 Wl of ice-
cold lysis bu¡er (20 mM Tris-HCl, pH 7.4/137 mM
NaCl/1 mM MgCl2/1 mM CaCl2/1% Nonidet P-40/
10% (w/v) glycerol/1 mM Na3VO4/2 mM EDTA/
1 mM PMSF/20 WM leupeptin and aprotinin at
0.15 U/ml) for 20 min at 4‡C with intermittent shak-
ing [38]. Detergent insoluble material was pelleted by
centrifugation (10 000Ug, 15 min, 4‡C). The protein
concentration in the detergent soluble fraction was
determined by Bradford method [40]. The solubilized
proteins were separated on 10% SDS-polyacrylamide
gel (20 Wg/lane) at 20 mA. The separated proteins
were transferred to nitrocellulose membrane (8 h at
125 mA) and were immunoblotted with anti-lyn anti-
bodies. The immunoblots were developed using the
chemiluminescence method following the manufac-
turer’s instructions (Boehringer Mannheim).
2.5. Immunoprecipitation of lyn
Immunoprecipitation of lyn was done essentially
as described [38] with some modi¢cations. Brie£y,
after treatment macrophage monolayers were lysed
in 50 Wl of ice-cold lysis bu¡er on ice for 10^20
min. Insoluble debris was removed by centrifugation
at 4‡C for 10 min at 12 000Ug. Protein content of
di¡erent samples was equalized after determining the
protein contents of di¡erent samples by Bradford
method [40]. The lyn protein was immunoprecipi-
tated from the lysates using 2 Wg/ml of polyclonal
anti-lyn antibodies followed by 10 Wl of protein-A-
agarose under rotation at 23‡C for 90 min. Immune-
complexes absorbed to protein-A-agarose were col-
lected by centrifugation in a microcentrifuge, fol-
lowed by ¢ve washes with 0.5 ml of cold lysis bu¡er.
After the last wash pellets were resuspended in kinase
assay bu¡er for tyrosine kinase activity determina-
tion [33].
2.6. In vitro immune-complex kinase assay
A peptide derived from the amino sequence sur-
rounding the phosphorylation site in pp60src, RR-
SRC (Arg-Arg-Leu-Ile-Glu-Asp-Ala-Glu-Tyr-Ala-
Glu-Tyr-Ala-Ala-Arg-Gly) (GIBCO/BRL), was uti-
lized as substrate [33] for above precipitated im-
mune-complexes. Ten Wl of protein-A-agarose immu-
noprecipitate was mixed with tyrosine kinase assay
bu¡er (30 nM HEPES (pH 7.4), 10 mM MgCl2,
0.1 mM dithiotreitol, 20 WM EDTA, 25 Wg/ml
BSA, 0.15% (vol/vol) NP-40, 70 WM Na3VO4,
60 WM ATP and 0.5 mM RR-SRC peptide) and
1 WCi [Q-32P]ATP. Reaction mixtures were incubated
at 30‡C for 30 min, stopped with 20 Wl ice-cold 10%
TCA, iced for 10 min, and microfuged for 10 min.
Twenty Wl of supernatant was spotted onto phospho-
cellulose discs, rinsed twice with 1% acetic acid and
twice with water and counts measured in scintillation
counter (LKB).
2.7. Cell viability
Macrophages were plated at a density of 105 cells/
well in 96-well plates in medium or medium contain-
ing 10 Wg/ml cisplatin in the absence or presence of
optimal dose of di¡erent inhibitors and modulators
for 24 h. Cytotoxic e¡ect of the inhibitor/modulator
was determined by the MTT assay [41]. Brie£y, the
cultures were washed and incubated for 2 h in me-
dium containing MTT (0.42 mg/ml), the medium was
removed, and the cells were lysed in acidi¢ed isopro-
panol (0.04 N HCl). The conversion of MTT to for-
mazon by metabolically viable cells was monitored
by a 96-well microplate reader at 570 nm (Molecular
Devices Emax). Percent cytotoxicity was calculated
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using the formula cytotoxicity (%)=[13(A/B)]U100,
where A is the absorbance of treated cells and B is
the absorbance of the control cells.
3. Results
3.1. Time kinetics of lyn expression and activation in
cisplatin-treated macrophages
The cell lysates of untreated and cisplatin-treated
macrophages were assayed for lyn expression by
Western blotting and for lyn activation by immune-
complex kinase assay as described in Section 2. Un-
treated macrophages showed a basal level of lyn ex-
pression which was signi¢cantly enhanced upon cis-
platin treatment of macrophages. Cisplatin-induced
up-regulation of lyn expression was observed within
5 min of treatment which peaked at 15 min. Sixty
min of cisplatin treatment to macrophages resulted in
a decline in the lyn expression as compared to the
macrophages treated with cisplatin for 15 min. A
second peak of lyn expression was observed at 2 h
of cisplatin treatment to macrophages, however, the
intensity of the second peak was much lower than
that of the ¢rst peak (Fig. 1A).
In vitro immune-complex kinase assay for protein
tyrosine kinase activity of lyn showed that untreated
macrophages possess a basal level of lyn kinase ac-
tivity (Fig. 1B). Cisplatin treatment to macrophages
resulted in a signi¢cantly increased lyn kinase activity
in a biphasic manner with the ¢rst peak at 15 min of
treatment and the second peak at 2 h of cisplatin
treatment. However, the second peak was not as
much pronounced as the ¢rst peak of lyn kinase
activity. Longer duration of cisplatin treatment did
not have any signi¢cant e¡ect on lyn kinase activity
as compared to the untreated macrophages (Fig. 1B).
3.2. The second peak of lyn is induced by soluble
products of cisplatin-treated macrophages
The second peak of lyn kinase activity may occur
by virtue of continuous presence of cisplatin in the
culture medium or may be secondarily induced by
autocrine action of some soluble products of cispla-
tin-treated macrophages. To check this possibility,
macrophage monolayers were treated with cisplatin
in a large excess of medium (2.5 ml/well of 24-well
culture plate) for 2 h or were treated with cisplatin
for 15 min. The medium of macrophages treated
with cisplatin for 15 min was replenished with fresh
medium containing cisplatin after every 30 min (to
remove the soluble products of macrophages) and
the macrophages were incubated at 37‡C for a total
of 2 h. After incubation cell lysates of macrophages
were assayed for the expression of lyn by immuno-
blotting and for lyn kinase activity by immune-com-
plex kinase assay. Replenishment of cisplatin-con-
taining medium did not change the second phase of
lyn expression (Fig. 2A, CP, CP) as compared to the
macrophages continuously treated with cisplatin for
Fig. 1. Time kinetics of lyn expression and activation. Perito-
neal macrophages (2U106 cells/well of 24-well tissue culture
plate) were treated with cisplatin (10 Wg/ml) for di¡erent time
intervals. A: Cell lysates were assayed for lyn expression by im-
munoblotting. B: lyn was immunoprecipitated from cell lysates
using lyn antibody and protein A-agarose. Immune-complex
kinase assay was performed using [Q-32P]ATP and a synthetic
substrate peptide (PR-SRC). Radioactivity incorporated into
PR-SRC was quantitated by scintillation counting after spotting
the assay mixture on to P81 ¢lter paper. Values represent
means ( þ S.D.) of duplicate determinations. Results are repre-
sentative of three similar experiments. *P6 0.05; versus value
of untreated macrophages.
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2 h (Fig. 2A, CP 120P). However, replenishment of
cisplatin-containing medium resulted in the disap-
pearance of the second peak of lyn kinase activity
(Fig. 2B).
3.3. E¡ect of serine/threonine and protein tyrosine
kinase and phosphatase inhibitors on lyn
expression and activation in cisplatin-treated
macrophages
To understand the role of kinases and phospha-
tases in the regulation of lyn expression and activa-
tion macrophages were incubated with optimal dose
of various inhibitors of kinases and phosphatases in
the absence or presence of cisplatin for 15 min. Re-
sults are shown in Fig. 3A and B. Macrophages
treated with cisplatin showed an increase in lyn ex-
pression and activation. Okadaic acid, an inhibitor of
PP2A at 1 nM concentration [42,43], marginally up-
regulated lyn expression and activation in both un-
treated and cisplatin-treated macrophages. Calyculin
A, an inhibitor of both PP1 and PP2A [42,43], in-
hibited lyn expression and activation in cisplatin-
Fig. 2. Second peak of lyn kinase activity is produced by solu-
ble factors released by cisplatin-treated macrophages. Peritoneal
macrophages (2U106) were incubated in medium alone (MED)
or were treated with 10 Wg/ml cisplatin for 15 min (CP 15P) or
for 2 h (CP 120P). In another set macrophages were treated
with cisplatin for 15 min and then the medium was replenished
with cisplatin-containing medium after every 30 min (CP, CP).
This set was incubated for a total of 2 h. lyn expression was as-
sayed by immunoblotting (A) and the lyn kinase activity was
determined by immune-complex kinase assay. Values represent
means ( þ S.D.) of duplicate determinations. Results are repre-
sentative of three similar experiments.
Fig. 3. E¡ect of phosphatases and kinases inhibitors on lyn ex-
pression and activation. Peritoneal macrophages (2U106 cells/
well of 24-well tissue culture plate) were incubated in medium
alone (MED) or were treated with cisplatin (10 Wg/ml) for 15
min in the absence or presence of 1 nM okadaic acid (OA) or
3 nM calyculin A (CA) or 20 WM H-7 or 100 WM sodium or-
thovanadate (SO) or 10 Wg/ml genestein (GEN). Lyn expression
(A) was determined by immunoblotting and lyn activation (B)
was determined by immune-complex kinase assay. Values are
means þ S.D. and are representative of three independent ex-
periments done in duplicate. *P6 0.05; versus value of un-
treated macrophages. #P6 0.05, versus value of cisplatin-
treated macrophages.
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treated macrophages but it had no signi¢cant e¡ect
on the basal level of lyn expression and activation in
resident macrophages. H-7, an inhibitor of PKC [44],
signi¢cantly inhibited lyn expression and activation
in both untreated and cisplatin-treated macrophages.
Sodium orthovanadate, an inhibitor of protein tyro-
sine phosphatases [23], signi¢cantly up-regulated lyn
expression and activation in both untreated and cis-
platin-treated macrophages. Genestein, an inhibitor
of protein tyrosine kinases [22], markedly inhibited
lyn expression and activation in both untreated and
cisplatin-treated macrophages (Fig. 3A and B).
3.4. E¡ect of Ca2+/calmodulin and calmodulin-
dependent kinase modulators on lyn expression
and activation
To determine if Ca2, calmodulin and calmodulin-
dependent kinase are required for the regulation of
lyn expression and activation, macrophages were in-
cubated in medium alone or medium containing op-
timal dose of various modulators or inhibitors in the
absence or presence of cisplatin for 15 min at 37‡C.
EGTA, a Ca2 chelator [45]; TMB-8, an intracellular
Ca2 immobilization agent [46]; nifedipine, a Ca2
channel blocker [47] ; W-7, a calmodulin antagonist
[48]; calmidazolium, an inhibitor of calmodulin-de-
pendent kinase [48] signi¢cantly inhibited lyn expres-
sion and activation in both untreated and cisplatin-
treated macrophages (Fig. 4).
3.5. Inhibitors/modulators are not cytotoxic
The suppression of cisplatin-induced lyn expres-
sion and activation by di¡erent inhibitors and mod-
ulators was not due to nonspeci¢c cytotoxicity to
macrophages. Viability of macrophages incubated
for 24 h with di¡erent inhibitors/modulators was
measured. None of the inhibitors at the concentra-
tion used in this study decreased the viability of the
macrophages as measured by the MTT assay (data
not shown).
4. Discussion
Although signi¢cant evidence has recently accumu-
lated implicating a signalling role for tyrosine phos-
phorylation, little is known about the mechanism(s)
leading to the observed induction of the tyrosine
phosphorylation in murine peritoneal macrophages
activated with cisplatin [21]. The data presented
here identify one enzymatic pathway, the expression
and activation of which is induced by cisplatin,
namely that dependent on the src-related tyrosine
kinase lyn.
Treatment of macrophages with cisplatin led to a
rapid and time-dependent increase in the expression
and activation of lyn. The activation of kinase activ-
ity of lyn was detectable as early as 5 min of cisplatin
treatment to macrophages with maximum kinase ac-
Fig. 4. E¡ect of Ca2 modulators on lyn expression and activa-
tion. Peritoneal macrophages (2U106 cells/well of 24-well tissue
culture plate) were incubated in medium alone (MED) or were
treated with cisplatin (10 Wg/ml) for 15 min in the absence or
presence of 2 mM EGTA, 100 WM TMB-8 (TMB), 10 WM nife-
dipine (NIF), 50 WM W-7 or 1 WM calmidazolium (CALM).
Lyn expression (A) was determined by immunoblotting and lyn
activation (B) was determined by immune-complex kinase assay.
Values are means þ S.D. and are representative of three inde-
pendent experiments done in duplicate. *P6 0.05; versus value
of untreated macrophages. #P6 0.05, versus value of cisplatin-
treated macrophages.
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tivity at 15 min of treatment. Kumar et al. [21] have
reported that the maximum protein tyrosine phos-
phorylation of cellular proteins in macrophages oc-
curs at 15 min of cisplatin treatment, which corre-
sponds to the time required for the maximal
activation of lyn in cisplatin-treated macrophages.
These observations suggest that lyn may be involved
in the initiation of cisplatin-induced signalling pro-
cesses leading to the activation of macrophages [12^
16]. This is supported by the observations that gen-
estein, a speci¢c inhibitor of protein tyrosine kinases,
inhibits both lyn kinase activity (present study) and
macrophage activation by cisplatin [12^16].
Lyn expression and activation in cisplatin-treated
macrophages followed a biphasic time kinetics (Fig.
2A and B). Results of medium replenishment experi-
ments indicate that appearance of second phase of
lyn expression and second phase of lyn activation are
two unrelated processes, because removal of cispla-
tin-containing medium prevented the appearance of
second phase of lyn kinase activity but had no e¡ect
on the second phase of lyn expression (Fig. 2A and
B; CP, CP compared with CP 120P). Therefore, it is
suggested that the second phase of lyn kinase activity
is due to the autocrine action of some soluble prod-
ucts, whereas the second phase of lyn expression
seems to be due to some intracellular factor in cis-
platin-treated macrophages. Recently it has been ob-
served that NF-UB translocation [14] and antigen
presentation [49] by cisplatin-treated macrophages
are biphasic processes. The second phase of NF-UB
translocation in cisplatin-treated macrophages was
due to the production of reactive oxygen intermedi-
ates [14] and the second phase of antigen presenta-
tion was due to the autocrine action of IL-1 and
TNF [49]. However, these factors were not responsi-
ble for the appearance of second phase of lyn expres-
sion or lyn activation (data not shown).
In the next part of the study an attempt was made
to understand the mechanism of lyn expression and
activation in cisplatin-treated macrophages with re-
spect to various kinases and phosphatases. Okadaic
acid, an inhibitor of PP2A increased lyn expression
and activation in both untreated and cisplatin-
treated macrophages. However, calyculin A, a potent
inhibitor of both PP1 and PP2A, inhibited lyn ex-
pression and lyn kinase activity in untreated and cis-
platin-treated macrophages. These observations indi-
cate that both PP1 and PP2A play a role in lyn
expression and activation but they act antagonisti-
cally (Fig. 3). Previously, okadaic acid and calyculin
A have been reported to exert di¡erent regulatory
mechanisms over cellular processes [50]. Sung and
Walters [50] have shown that calyculin A inhibits
IL-K, IL-1L and IL-6 mRNA accumulation in LPS-
treated monocytes whereas okadaic acid was ob-
served to have no e¡ect. Sodium orthovanadate
treatment of resident macrophages signi¢cantly aug-
mented lyn kinase activity, however, no change was
observed in lyn expression (compare Fig. 3A and B).
Cisplatin-induced expression and activation of lyn
was further enhanced in the presence of sodium or-
thovanadate. Recent reports suggest that inhibition
of basal level PTPs activity in resting cells results in a
positive response [10^12,24^29]. Therefore, it is sug-
gested that sodium orthovanadate-induced activation
of resident macrophages and up-regulation of cispla-
tin-induced macrophage activation [10^12] may be
due to its e¡ect on lyn kinase activity. PKC and
PTK inhibitors have been shown to inhibit macro-
phage activation by IFN-Q, LPS or cisplatin [12,14^
16,51,52]. It was observed in this study that genes-
tein, an inhibitor of PTK, and H-7, an inhibitor of
PKC, inhibited lyn expression and activation in un-
treated and cisplatin-treated macrophages (Fig. 3). It
is possible that inhibitory e¡ect of these agents on
cisplatin-induced macrophage activation [12,14^16] is
due to their inhibitory e¡ect on lyn expression and
activation.
Ca2 ions are ubiquitous intracellular signalling
molecules which control a wide array of cellular
processes [39,53^56]. Cisplatin has been shown to
increase the intracellular Ca2 level in macrophage
[39]. Present study indicates that Ca2/calmodulin
and calmodulin-dependent kinase activities are essen-
tial for expression and activation of lyn in macro-
phages. It was observed in resting macrophages and
cisplatin-treated macrophages that chelation of Ca2
by EGTA, immobilization of intracellular Ca2 ions
by TMB-8, blockage of Ca2 channels by nifedipine
and inhibition of calmodulin and calmodulin-de-
pendent kinase by W-7 and calmidazolium respec-
tively, inhibited lyn expression and activation. Using
the same set of modulators it has been observed that
cisplatin-induced macrophage activation is depen-
dent on the activity of Ca2/calmodulin and cal-
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modulin-dependent kinase [14^16,39]. Therefore, it is
suggested that inhibition of cisplatin-induced macro-
phage activation by Ca2/calmodulin and calmodu-
lin-dependent kinase modulators [14^16,39] may in-
volve their inhibitory e¡ect on lyn expression and
activation in cisplatin-treated macrophages.
Data presented in this study suggest that cisplatin-
induced murine peritoneal macrophage activation in-
volves expression and activation of lyn, a src-related
membrane-associated protein tyrosine kinase. Mech-
anism of lyn expression and activation in cisplatin-
treated macrophages with respect to various kinases,
phosphatases and Ca2/calmodulin has also been
worked out. Since a number of autoimmune diseases
have been reported in lyn-de¢cient mice [57], our
study may have some interesting implications in the
clinical trials with cisplatin.
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